4.7 Article

Polymeric nanoengineered HBsAg DNA vaccine designed in combination with β-glucan

期刊

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijbiomac.2018.11.024

关键词

DNA HBsAg; PDMAEMA:P beta AE; beta-Glucan

资金

  1. European Regional Development Fund (ERDF), through the Centro 2020 Regional Operational Programme [CENTRO-01-0145-FEDER-000008:BrainHealth 2020]
  2. European Regional Development Fund (ERDF), through COMPETE 2020 - Operational Programme for Competitiveness and Internationalisation
  3. Portuguese national funds via FCT - Fundacao para a Ciencia e a Tecnologia, I.P. [PROSAFE/0001/2016, POCI-01-0145-FEDER-007440 (UID/NEU/04539/2013), POCI-01-0145-FEDER-030331]
  4. FCT [DFRH - SFRH/BD/96167/2013]
  5. Fundação para a Ciência e a Tecnologia [ProSafe/0001/2016] Funding Source: FCT

向作者/读者索取更多资源

Antigen-specific immune responses following DNA vaccination are hard to achieve, owing to the difficulty to mediate efficient gene delivery. This study proposed the use of PDMAEMA:P beta AE/DNA polyplexes (Pol) as the vehicle of a pDNA vaccine encoding the hepatitis B surface antigen (HBsAg), with these Pol designed in combination with a soluble (Glu) or a particulate (GPs) form of beta-glucan. beta-Glucans are recognized adjuvants that activate immune cells, a good strategy to improve transfection efficiency and vaccine efficacy. Results showed that Pol produced at a 19:1 polymer:DNA (+/-) charge ratio were positively charged (+41 mV), had a mean size of 180 nm and presented high stability under different storage conditions. These polyplexes resulted in enhanced transfection activity than the positive control, showing even higher luciferase gene expression in the presence of GPs (COS-7 and RAW 264.7 cell lines). Additionally, no alterations in hemolysis and plasma coagulation time of human blood were found in the non-cytotoxic working range. Mice vaccination studies (pCMV-S), resulted in a seroconversion rate of 40%, regardless of the additional beta-glucan adjuvants. This work showed the potential of this nano system together with GPs to enhance in vitro transfection capacity and to be further studied as a DNA vaccination platform. (C) 2018 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据